Creative Edge Nutrition Inc (FITX)

[bulls9999]

Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential

http://jop.sagepub.com/content/19/3/293.short

C. H. Ashton, P. B. Moore, P. Gallagher, A. H. Young Department of Psychiatry, University of Newcastle upon Tyne, Royal Victoria Infirmary, Newcastle upon Tyne, UK

Abstract

Bipolar affective disorder is often poorly controlled by prescribed drugs. Cannabis use is common in patients with this disorder and anecdotal reports suggest that some patients take it to alleviate symptoms of both mania and depression. We undertook a literature review of cannabis use by patients with bipolar disorder and of the neuropharmacological properties of cannabinoids suggesting possible therapeutic effects in this condition. No systematic studies of cannabinoids in bipolar disorder were found to exist, although some patients claim that cannabisrelieves symptoms of mania and/or depression. The cannabinoids ?9-tetrahydrocannabinol (THC) and cannabidiol (CBD) may exert sedative, hypnotic, anxiolytic, antidepressant, antipsychotic and anticonvulsant effects. Pure synthetic cannabinoids, such as dronabinol and nabilone and specific plant extracts containing THC, CBD, or amixture of the two in known concentrations, are available and can be delivered sublingually. Controlled trials of these cannabinoids as adjunctive medication in bipolar disorder are now indicated.


Cannabidiol was ineffective for manic episode of bipolar affective disorder
J Psychopharmacol January 1, 2010 24: 135-137
Abstract, Full Text (PDF)

Cannabis use by people with severe mental illness - is it important?
Adv. Psychiatr. Treat. November 1, 2008 14: 423-431
Abstract, Full Text (PDF)

Cannabinoids Elicit Antidepressant-Like Behavior and Activate Serotonergic Neurons through the Medial Prefrontal Cortex
J. Neurosci. October 24, 2007 27: 11700-11711
Abstract, Full Text (PDF)

Cannabis use increases risk of developing symptoms of mania
Evid. Based Ment. Health May 1, 2007 10: 61

The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pharmacol. Rev. September 1, 2006 58: 389-462
Abstract

Ethanol Potentiates GABAergic Synaptic Transmission in a Postsynaptic Neuron/Synaptic Bouton Preparation From Basolateral Amygdala
J. Neurophysiol. July 1, 2006 96: 433-441
Abstract, Full Text (PDF)

I didn't realize the amount of studies on this and how far back they go. There is a wealth of medical studies supporting cannabinoids and their medical effectiveness.